We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Radiotherapy Doubles Mesothelioma Survival Rate

By MedImaging International staff writers
Posted on 15 May 2019
Print article
Mesothelioma patients treated with a high dose of radiation to the affected side of the trunk are twice as likely to survive for two years or longer, according to a new study.

Researchers at University Hospital of Udine (Italy) and the National Cancer Institute (CRO; Aviano, Italy) conducted a study that involved 108 patients with malignant pleural mesothelioma treated between 2014 and 2018 at the CRO. Half of the patients were randomly assigned to receive radical hemi-thoracic radiotherapy (RT) involving a total of 25 treatments, delivering a total dose of 50 Gy to the left or right side of the trunk, as well as an extra 60 Gy dose to the precise location of the tumor.

The other half of the patients received a more typical palliative form of RT, which involved five to ten treatments delivering a total dose of 20-30 Gy to the precise tumor location. All patients also received subsequent chemotherapy. The results showed that of the patients who received aggressive RT, 58% were still alive two years later, compared to 28% in the palliative RT group. Treatment side effects included radiation pneumonitis, weakness, nausea, and mild inflammation of the esophagus. The study was presented at the ESTRO 38 annual conference, held during April 2019 in Milan (Italy).

“There is an urgent need for more effective treatments for mesothelioma. Surgery can be given to these patients, but it is often impossible to remove all of the tumor,” said lead author Marco Trovo MD, chief of the radiation oncology department. “This research shows a clear survival benefit in using this type of radiotherapy for mesothelioma patients whose tumors can only partially be removed by surgery. We believe that this should be considered the new standard of care for these patients.”

Mesothelioma develops from the mesothelium lining that covers many of the internal organs; the most common area affected is the lining of the lungs and chest wall. Signs and symptoms include shortness of breath due to fluid around the lung, a swollen abdomen, chest wall pain, cough, exhaustion, and weight loss. More than 80% of mesothelioma cases are caused by exposure to asbestos, with exposure and the onset of cancer generally separated by about 40 years. Mesothelioma is generally resistant to radiation and chemotherapy treatment, and long-term survival and cures are exceedingly rare.

Related Links:
University Hospital of Udine
National Cancer Institute

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
CT Phantom
CIRS Model 610 AAPM CT Performance Phantom
New
X-Ray Detector
FDR-D-EVO III
New
Pre-Op Planning Solution
Sectra 3D Trauma

Print article

Channels

MRI

view channel
Image: Diamond dust offers a potential alternative to the widely used contrast agent gadolinium in MRI (Photo courtesy of Max Planck Institute)

Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans

Gadolinium, a heavy metal used for over three decades as a contrast agent in medical imaging, enhances the clarity of MRI scans by highlighting affected areas. Despite its utility, gadolinium not only... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.